Treatment of Guillain-Barré syndrome with a standard course of high-dose intravenous immunoglobulin (IVIg) results in a variable clinical recovery which is associated with changes in serum IgG levels after treatment. The neonatal Fc-receptor protects IgG from degradation, and a genetic polymorphism in its promoter region that influences the expression of Fc-receptor, may in part explain the variation in IgG levels and outcome. This polymorphism was determined by polymerase chain reaction in a cohort of 257 patients with Guillain-Barré syndrome treated with IVIg. We could not demonstrate a relation between this polymorphism, the pharmacokinetics of IVIg, or the clinical course and outcome.

Additional Metadata
Persistent URL dx.doi.org/10.1002/acn3.307, hdl.handle.net/1765/101581
Journal Annals of Clinical and Translational Neurology
Citation
Fokkink, W.-J.R, Haarman, A.E.G. (Annechien E. G.), Tio-Gillen, A.P, van Rijs, W, Huizinga, R, van Doorn, P.A, & Jacobs, B.C. (2016). Neonatal Fc receptor promoter gene polymorphism does not predict pharmacokinetics of IVIg or the clinical course of GBS. Annals of Clinical and Translational Neurology, 547–551. doi:10.1002/acn3.307